EUVIMEDEUVIMED entdecken
Crossref

Hydroxychloroquine Dose and Risk for Incident Retinopathy

Ronald B Melles iD, April M Jorge iD, Michael F Marmor, Baijun Zhou, Carol Conell iD, Jingbo Niu, Natalie McCormick iD, Yuqing Zhang iD, Hyon K Choi

Annals of Internal Medicine · 2023-02 · 176 (2) · 166-173

DOI: 10.7326/m22-2453 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annals of Internal Medicine, 2023-02. Verfasst von Ronald B Melles und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, Kaiser Permanente Northern California, Redwood City, California (R.B.M.). Hauptthemen laut MEDLINE: Antirheumatic Agents, Retinal Diseases, Lupus Erythematosus, Systemic. Die Arbeit wurde bisher 59-mal zitiert (Crossref) und nennt 32 Literaturangaben. Gefördert von: National Institute of Arthritis and Musculoskeletal and Skin Diseases, Rheumatology Research Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Hydroxychloroquine is recommended for all patients with systemic lupus erythematosus and is often used for other inflammatory conditions, but a critical long-term adverse effect is vision-threatening retinopathy. OBJECTIVE: To characterize the long-term risk for incident hydroxychloroquine retinopathy and examine the degree to which average hydroxychloroquine dose within the first 5 years of treatment predicts this risk. DESIGN: Cohort study. SETTING: U.S. integrated health network. PARTICIPANTS: All patients aged 18 years or older who received hydroxychloroquine for 5 or more years between 2004 and 2020 and had guideline-recommended serial retinopathy screening. MEASUREMENTS: Hydroxychloroquine dose was assessed from pharmacy dispensing records. Incident hydroxychloroquine retinopathy was assessed by central adjudication of spectral domain optical coherence tomography with severity assessment (mild, moderate, or severe). Risk for hydroxychloroquine retinopathy was estimated over 15 years of use according to hydroxychloroquine weight-based dose (>6, 5 to 6, or ≤5 mg/kg per day) using the Kaplan-Meier estimator. RESULTS: Among 3325 patients in the primary study population, 81 developed hydroxychloroquine retinopathy (56 mild, 17 moderate, and 8 severe), with overall cumulative incidences of 2.5% and 8.6% at 10 and 15 years, respectively. The cumulative incidences of retinopathy at 15 years were 21.6% for higher than 6 mg/kg per day, 11.4% for 5 to 6 mg/kg per day, and 2.7% for 5 mg/kg per day or lower. The corresponding risks for moderate to severe retinopathy at 15 years were 5.9%, 2.4%, and 1.1%, respectively. LIMITATION: Possible misclassifications of dose due to nonadherence to filled prescriptions. CONCLUSION: In this large, contemporary cohort with active surveillance retinopathy screening, the overall risk for hydroxychloroquine retinopathy was 8.6% after 15 years, and most cases were mild. Higher hydroxychloroquine dose was associated with progressively greater risk for incident retinopathy. PRIMARY FUNDING SOURCE: National Institutes of Health.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antirheumatic AgentsRetinal DiseasesLupus Erythematosus, SystemicHumansHydroxychloroquineCohort Studies

Substanzen

HydroxychloroquineAntirheumatic Agents

Autor:innen und Institutionen

  • Department of Ophthalmology, Kaiser Permanente Northern California, Redwood City, California (R.B.M.).
  • Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, and Harvard Medical School, Boston, Massachusetts (A.M.J., Y.Z., H.K.C.).
  • Department of Ophthalmology and Byers Eye Institute, Stanford University School of Medicine, Palo Alto, California (M.F.M.).
  • Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Boston, Massachusetts (B.Z.).
  • Division of Research, Kaiser Permanente Northern California, Oakland, California (C.C.).
  • Department of Medicine, Baylor College of Medicine, Houston, Texas (J.N.).

ORCID-Profile: Ronald B Melles, April M Jorge, Carol Conell, Natalie McCormick, Yuqing Zhang

Förderung

  • National Institute of Arthritis and Musculoskeletal and Skin Diseases
  • Rheumatology Research Foundation

Zitieren

APA

Melles, R. B., Jorge, A. M., Marmor, M. F., Zhou, B., Conell, C., Niu, J., McCormick, N., Zhang, Y., & Choi, H. K. (2023). Hydroxychloroquine Dose and Risk for Incident Retinopathy. Annals of Internal Medicine, 176(2), 166-173. https://doi.org/10.7326/m22-2453

Vancouver

Melles RB, Jorge AM, Marmor MF, Zhou B, Conell C, Niu J, et al. Hydroxychloroquine Dose and Risk for Incident Retinopathy. Annals of Internal Medicine. 2023;176(2):166-173. doi:10.7326/m22-2453

BibTeX
@article{Melles2023,
  author = {Melles, Ronald B and Jorge, April M and Marmor, Michael F and Zhou, Baijun and Conell, Carol and Niu, Jingbo and McCormick, Natalie and Zhang, Yuqing and Choi, Hyon K},
  title = {Hydroxychloroquine Dose and Risk for Incident Retinopathy},
  journal = {Annals of Internal Medicine},
  year = {2023},
  volume = {176},
  number = {2},
  pages = {166--173},
  doi = {10.7326/m22-2453}
}
Kostenlos starten →